Corporate Members
FDA and NCCN Approvals
NCCN Guidelines® Now Recommend a New
Treatment Option for Extensive-stage SCLC
Treatment Option for Extensive-stage SCLC
The FDA has approved a new indication for IMFINZI® (durvalumab), in combination with platinum containing chemotherapy as neoadjuvant treatment, followed by IMFINZI continued as a single agent as adjuvant treatment after surgery, is
indicated for the treatment of adult patients with resectable (tumors ≥ 4 cm and/or node positive) non-small cell lung cancer
(NSCLC) and no known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements. Approval was based on results from the Phase III, global, doubleblind, placebo-controlled AEGEAN trial.1
indicated for the treatment of adult patients with resectable (tumors ≥ 4 cm and/or node positive) non-small cell lung cancer
(NSCLC) and no known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements. Approval was based on results from the Phase III, global, doubleblind, placebo-controlled AEGEAN trial.1